Advice
Recommended for general use within NHS Scotland.
Indication Under Review:
primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet, when response to diet and exercise is inadequate.
homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid-lowering treatments (e.g. LDL apheresis).
Recommendation
Rosuvastatin is a new HMG-CoA reductase inhibitor, with costs and efficacy in reducing low-density-lipoprotein-cholesterol (LDL-C) comparable to other statins. Its current licenced indications are more limited than some other statins.
Download detailed advice41KB (PDF)
Medicine details
- Medicine name:
- rosuvastatin (Crestor)
- SMC ID:
- 45/03
- Indication:
- Primary hypercholesterolaemia or mixed dyslipidaemia
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2003